![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC22A15 |
Gene summary for SLC22A15 |
![]() |
Gene information | Species | Human | Gene symbol | SLC22A15 | Gene ID | 55356 |
Gene name | solute carrier family 22 member 15 | |
Gene Alias | FLIPT1 | |
Cytomap | 1p13.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q8IZD6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55356 | SLC22A15 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 2.26e-12 | 6.50e-01 | -0.2116 |
55356 | SLC22A15 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 5.42e-07 | 6.59e-01 | -0.1941 |
55356 | SLC22A15 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 2.45e-05 | 5.72e-01 | -0.2107 |
55356 | SLC22A15 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 1.98e-08 | 5.11e-01 | -0.2119 |
55356 | SLC22A15 | HTA12-23-1 | Human | Pancreas | PDAC | 2.25e-04 | 5.03e-01 | 0.3405 |
55356 | SLC22A15 | HTA12-25-1 | Human | Pancreas | PDAC | 3.68e-04 | 4.26e-01 | 0.313 |
55356 | SLC22A15 | HTA12-26-1 | Human | Pancreas | PDAC | 7.38e-20 | 7.68e-01 | 0.3728 |
55356 | SLC22A15 | HTA12-29-1 | Human | Pancreas | PDAC | 5.31e-31 | 7.00e-01 | 0.3722 |
55356 | SLC22A15 | HTA12-32-1 | Human | Pancreas | PDAC | 1.46e-03 | 6.91e-01 | 0.3624 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC22A15 | SNV | Missense_Mutation | c.1624N>A | p.Glu542Lys | p.E542K | Q8IZD6 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.76) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
SLC22A15 | SNV | Missense_Mutation | c.492N>A | p.Phe164Leu | p.F164L | Q8IZD6 | protein_coding | tolerated(0.45) | benign(0.01) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
SLC22A15 | deletion | Frame_Shift_Del | novel | c.509delT | p.Phe170SerfsTer5 | p.F170Sfs*5 | Q8IZD6 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
SLC22A15 | SNV | Missense_Mutation | c.939N>A | p.Phe313Leu | p.F313L | Q8IZD6 | protein_coding | deleterious(0.05) | benign(0.16) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC22A15 | SNV | Missense_Mutation | c.787N>C | p.Glu263Gln | p.E263Q | Q8IZD6 | protein_coding | tolerated(0.31) | benign(0.045) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SLC22A15 | SNV | Missense_Mutation | c.1036A>G | p.Ile346Val | p.I346V | Q8IZD6 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC22A15 | SNV | Missense_Mutation | c.492C>A | p.Phe164Leu | p.F164L | Q8IZD6 | protein_coding | tolerated(0.45) | benign(0.01) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLC22A15 | SNV | Missense_Mutation | rs375814433 | c.1328N>A | p.Arg443Gln | p.R443Q | Q8IZD6 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-AA-3819-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC22A15 | SNV | Missense_Mutation | rs754520667 | c.806N>G | p.Ala269Gly | p.A269G | Q8IZD6 | protein_coding | tolerated(0.15) | possibly_damaging(0.666) | TCGA-AA-3955-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | capecitabine | CR |
SLC22A15 | SNV | Missense_Mutation | c.602N>T | p.Ser201Leu | p.S201L | Q8IZD6 | protein_coding | deleterious(0) | benign(0.251) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |